|
|
Weekly Digest
June 16, 2026
Volume 3, Issue 3
|
|
What’s Inside This Week
A widening Salmonella outbreak tied to moringa leaf powder supplements leads the week, with 119 illnesses now confirmed across 36 states, 32 hospitalizations and an expanded recall, reviving long-running questions about the FDA’s largely reactive authority over supplement safety under DSHEA. On the claims front, a California court closed more than a decade of Joint Juice litigation with roughly $90 million in settlements, a reminder that structure/function claims offer no shelter once advertising is found deceptive. Regulators also sharpened expectations around AI-generated compliance records, while the industry logged fresh deal activity, a major microbiome funding commitment and new clinical data on krill oil, cognitive ingredients and gene-editing science.
|
|
|
|
FDA warning letter underscores the risks of AI in compliance documents
NutraIngredients | June 15, 2026
The FDA issued a warning letter to Michigan-based Purolea Cosmetics Lab citing Good Manufacturing Practice and disease-claim violations after the firm used AI to generate compliance records that omitted required process validation. It is the agency’s fourth warning letter to reference artificial intelligence and the first to detail best practices for the technology in quality systems. Compliance experts stress that supplement and drug makers remain responsible for human review of any AI-generated GMP documentation.
|
|
|
After 12 years, Joint Juice litigation ends with $90M in settlements
NutraIngredients | June 9, 2026
A California court granted final approval to roughly $90 million in settlements resolving more than a decade of class-action litigation over joint-health claims for Premier Nutrition’s glucosamine and chondroitin beverage Joint Juice. Plaintiffs argued the structure/function claims lacked reliable scientific support, and courts weighed the overall impression the labeling conveyed to a reasonable consumer. The outcome signals that DSHEA structure/function claims provide no protection when advertising is deemed deceptive, reinforcing the need for rigorous claim substantiation.
|
|
Recalls & Supplement Safety
|
|
Salmonella outbreak linked to moringa supplements expands to 119 cases across 36 states
Medical Daily | June 9, 2026
A Salmonella outbreak tied to moringa leaf powder supplements has grown to 119 illnesses across 36 states, with 32 hospitalizations and some cases linked to an extensively drug-resistant strain. Federal officials reopened the investigation in May after declaring it over in March, with illness onsets stretching back to August 2025. The case renews scrutiny of the DSHEA framework, under which supplements are not tested for contamination before reaching shelves and FDA action remains largely reactive.
|
|
|
Recall of moringa capsules implicated in Salmonella outbreak expanded
Food Safety News | June 12, 2026
Total Nutrition Inc. of Deer Park, New York expanded its recall of TNVitamins and Doctor’s Pride moringa capsules after a supply-chain traceability review flagged additional lots tied to the same contaminated raw material. The products were distributed nationally through Amazon, Walmart, TikTok Shop, Target and the company’s own websites. Consumers are urged to dispose of affected lots immediately as the FDA and CDC investigation continues.
|
|
Industry, Deals & Market Trends
|
|
Function acquires SuppCo to connect supplement recommendations with health data
NutraIngredients | June 15, 2026
Health platform Function, which offers lab testing, imaging and clinician-reviewed insights, has acquired supplement-intelligence platform SuppCo, whose TrustScore rates more than 35,000 products. The companies aim to link biomarker data with independent supplement evaluation so recommendations are driven by biology rather than marketing claims. Financial terms of the deal were not disclosed.
|
|
|
Weston Family Foundation commits C$37 million to microbiome interventions
NutraIngredients | June 10, 2026
The Weston Family Foundation launched its Microbiome Innovations for New Therapies (MINT) program, committing C$37 million over seven years to move microbiome-based interventions toward clinical trials. Unveiled at Probiota Americas in Vancouver, the initiative is open to probiotics, prebiotics, postbiotics, fecal transplants and bacteriophages. It marks the foundation’s largest microbiome funding commitment to date.
|
|
Science & Ingredient Research
|
|
Krill oil outperforms fish oil in raising omega-3 plasma levels
NutraIngredients | June 9, 2026
A 12-week randomized controlled trial in 72 adults found krill oil raised circulating EPA and DHA roughly 1.5 times more than fish oil at a matched dose of about 1.1 grams per day. Researchers attributed the difference to krill oil’s phospholipid structure rather than greater absorption, and noted sex-based differences in EPA response. The authors cautioned that higher plasma levels do not automatically translate into superior clinical outcomes.
|
|
|
OmniActive ingredient boosts cognitive performance when paired with caffeine
NutraIngredients | June 9, 2026
Newly published clinical research found OmniActive’s proprietary Alpinia galanga extract, enXtra, sustained mental alertness and reduced fatigue both alone and combined with caffeine, helping curb the so-called caffeine crash. The randomized, double-blind, placebo-controlled study enrolled more than 120 habitual caffeine consumers. Researchers reported that enXtra delivered longer-lasting cognitive benefits than caffeine alone, whose effects faded after the first hour.
|
|
|
From bench to biome: CRISPR phages could precision-edit the microbiome
NutraIngredients | June 15, 2026
At Probiota Americas 2026, a North Carolina State University researcher described how CRISPR-engineered bacteriophages could edit the gut microbiome in place by delivering targeted genetic payloads to specific microbes. Therapeutic uses such as treating bacterial infections are already in clinical trials, but applications in dietary supplements remain years away. The work points to how far-reaching precision microbiome tools may eventually reshape the category.
|
|
|
Your Voice Matters
As the FDA weighs DSHEA modernization, from the scope of dietary ingredients to proposed changes to the disclaimer rule, industry and consumer input will shape the framework that protects access to safe supplements. Make sure your perspective is part of the record.
|
|
DSHEA Preservation Alliance | Protecting access to safe, beneficial dietary supplements.
You are receiving this email because you subscribed to the DSHEA Weekly Digest.
Unsubscribe | *|HTML:LIST_ADDRESS|*
Powered by PICXM
|
